Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer
Authors:
- Mehmet A. BilenMBMehmet A. Bilen
- Neal ShoreNSNeal Shore
- Sabree BurbageSBSabree Burbage
- Carmine RossiCRCarmine Rossi
- Lilian DiazLDLilian Diaz
- Ibrahim KhilfehIKIbrahim Khilfeh
- Yuxi WangYWYuxi Wang
- Gordon WongGWGordon Wong
- Dominic PilonDPDominic Pilon
- Benjamin LowentrittBLBenjamin Lowentritt
- Daniel W. LinDLDaniel W. Lin
Abstract
No abstract availableKeywords
Funding Information
- Flatiron Health
- Johnson and Johnson
- Janssen Pharmaceutica
This publication has 19 references indexed in Scilit:
- Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerAdvances in Therapy, 2025
- Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersJAMA Network Open, 2024
- Genetic Testing in Men With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2024
- Advancing health equity in the aftermath of COVID-19: Confronting intensifying racial disparitiesiScience, 2024
- Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genesAnnals of Oncology, 2024
- Assessment of Changes in Cancer Treatment During the First Year of the COVID-19 Pandemic in the USJAMA Oncology, 2024
- Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate CancerJAMA Network Open, 2023
- Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM TrialEuropean Urology Oncology, 2023
- Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate CancerJAMA Network Open, 2023
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialAnnals of Oncology, 2023